← Back to Search

[¹⁴C]-LY3437943 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose up to 63 days post dose

Awards & highlights

Study Summary

This trial will look at how a drug, LY3437943, circulates in the body and is removed, by testing a single dose with a radioactive tracer in healthy male participants over 15 weeks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose up to 63 days post dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose up to 63 days post dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 63 days post dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Secondary outcome measures

PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC (0-∞)) of Total Radioactivity and [¹⁴C]-LY3437943

PK: Maximum Concentration (Cmax) of Total Radioactivity and [¹⁴C]-LY3437943

Total Number of Metabolites of LY3437943

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: [¹⁴C]-LY3437943Experimental Treatment1 Intervention

Single dose of [¹⁴C]-LY3437943 administered subcutaneously (SC).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

[¹⁴C]-LY3437943

2023

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,616 Previous Clinical Trials

3,201,163 Total Patients Enrolled

Study DirectorEli Lilly and Company

1,345 Previous Clinical Trials

405,357 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an age threshold for individuals attempting to enroll in this clinical experiment?

"This study is open to any individual aged 18 or higher and below the age of 55."

Answered by AI

Would I qualify to be a participant of this experiment?

"To be eligible for the trial, candidates must have no preexisting conditions and fall between 18 to 55 years of age. Presently, 7 participants are required for the study."

Answered by AI

What potential risks are associated with the use of [¹⁴C]-LY3437943?

"Our team has assigned [¹⁴C]-LY3437943 a score of 1 due to the minimal amount of safety and efficacy data available, as this is only in the first phase."

Answered by AI

Is this research endeavor recruiting participants at the present time?

"Based on clinicaltrials.gov, this study is no longer actively recruiting patients. It was initially posted in March 17th of 2023 and last updated February 24th of the same year. Despite this trial's conclusion, there are still 820 other research initiatives seeking participants at present."

Answered by AI

What are the objectives of this medical experiment?

"This trial's primary objective, measured from pre-dose up to 63 days post dose is assessing the Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Secondary objectives include Maximum Concentration (Cmax) of Total Radioactivity and [¹⁴C]-LY3437943; total radioactivity recovered in urine, faeces, and expired air (if applicable); and the number of metabolites produced by LY3437943."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

2023. "A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05757531.